| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/05/2004 | US20040152663 Dissolving an amphiphilic heparin derivative comprising heparin covalently bonded to a hydrophobic agent selected from bile acids, sterols, alkanoic acids, and mixtures thereof in a water phase; dispersing in organic phase; drying emulsion |
| 08/05/2004 | US20040152662 Method for preventing, reducing, and treating radiation cystitis using hyaluronic acid |
| 08/05/2004 | US20040152661 Methods and compositions for treating viral diseases |
| 08/05/2004 | US20040152660 Autoinducer synthase modulating compounds and uses therefore |
| 08/05/2004 | US20040152659 For therapy and prophylaxis of Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder which contain as the active ingredient an adenosine A1A2a receptor dual antagonist or salts thereof |
| 08/05/2004 | US20040152658 For therapy of animal having a deficiency in a neuron's immediate early gene responsiveness to a stimulus |
| 08/05/2004 | US20040152657 Immunomodulatory oligonucleotides |
| 08/05/2004 | US20040152656 For use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics |
| 08/05/2004 | US20040152655 Antisense oligonucleotides that inhibit expression of HIF-1 |
| 08/05/2004 | US20040152653 Administering a pharmacologic complex to the airway epithelium via its luminal surface, wherein the complex comprises a ligand for serpin enzyme complex receptor (SecR) and a pharmacologic agent |
| 08/05/2004 | US20040152652 Therapy of inflammatory disorder in an individual comprising administering oligonucleotide up to 30 nucleotides in length complementary to a nucleic acid molecule encoding human tumor necrosis factor- alpha |
| 08/05/2004 | US20040152646 Useful in therapy of disorders which are responsive to the opening of potassium channels such as ischemia, stroke, convulsions, asthma, epilepsy, irritable bowel syndrome, migraine, traumatic brain injury, spinal cord injury, sexual dysfunction |
| 08/05/2004 | US20040152645 Antihelminthic anthraquinones and method of use thereof |
| 08/05/2004 | US20040152644 For therapy of neoplastic diseases |
| 08/05/2004 | US20040152643 For therapy of neoplastic diseases |
| 08/05/2004 | US20040152642 For therapy of of neoplastic diseases |
| 08/05/2004 | US20040152641 Use of polymethoxylated flavones for treating insulin resistance |
| 08/05/2004 | US20040152640 Use of one or members selected from the group consisting of apigenin, luteolin, morin and functional analogues thereof for manufacture of a preparation for the treatment and/or prevention of disorder related to altered bone metabolism in a mammal |
| 08/05/2004 | US20040152632 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| 08/05/2004 | US20040152631 Administering a drug which interacts with lumbar spinothalamic (LSt) cells and/or target cells of LSt cells to manipulate sensation of ejaculation in the individual |
| 08/05/2004 | US20040152630 14-3-3 Binding molecules as sensitizers for anticancer therapies |
| 08/05/2004 | US20040152627 For therapy of orthopaedic and dental, including periodontal, diseases |
| 08/05/2004 | US20040152626 Identification of novel splice variants of the human catalytic subunit cbeta of camp-dependent protein kinase and the use thereof |
| 08/05/2004 | US20040152625 Administering 5,11-Dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one and one or more inhibitors of CYP 450 for therapy of HIV |
| 08/05/2004 | US20040152623 Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| 08/05/2004 | US20040152612 Use as carrier systems for active ingredients from the ubiquinone class which are slightly soluble in water; suitable for oral administration in the form of unit dose forms |
| 08/05/2004 | US20040152164 62 human secreted proteins |
| 08/05/2004 | US20040152156 Nucleotide sequences coding counter-ligands for several receptors expressed on lymphocytes for use in diagnosis and treatment of asthma, allergic or inflammatory disease |
| 08/05/2004 | US20040152143 Growth differentiation factor-9 |
| 08/05/2004 | US20040152140 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 08/05/2004 | US20040152138 Using dementia related osteoponton (DROPN) peptides to diagnose, prognose and identify treatments for progressive neurodegenerative diseases |
| 08/05/2004 | US20040152134 Eating disorders; sexual disorders; erectile dysfunction |
| 08/05/2004 | US20040152112 Compositions and methods for cancer diagnosis and therapy |
| 08/05/2004 | US20040152111 Compositions and methods for diagnosing and treating mood disorders |
| 08/05/2004 | US20040152106 for drug screening treatments for huntington's disease/alzheimer's/parkinson's disease, schizophrenia, depression, anxiety, stress, trauma, stroke |
| 08/05/2004 | US20040152078 Genetic engineering |
| 08/05/2004 | US20040152073 Human cellular protein gastrointestinal glutathione peroxidase active materials |
| 08/05/2004 | US20040152042 Dispensing apparatus and cartridge with deformable tip |
| 08/05/2004 | US20040151824 Oil composition |
| 08/05/2004 | US20040151792 Compositions that treat or inhibit pathological conditions associated with inflammatory response |
| 08/05/2004 | US20040151791 an analgesic selected from morphine, meperidine, fentanyl, hydromorphone, oxymorphone, oxycodone, hydrocodone, methadone, propoxyphene, pentazocine, levorphanol and combinations and a stool softener |
| 08/05/2004 | US20040151790 Agent for preventing, improving or treating hypertension |
| 08/05/2004 | US20040151788 Method for increasing bone mineral density |
| 08/05/2004 | US20040151786 Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite |
| 08/05/2004 | US20040151785 Administering compound which stimulates nitric oxide production in the liver |
| 08/05/2004 | US20040151783 Therapeutic compositions |
| 08/05/2004 | US20040151782 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 08/05/2004 | US20040151781 Osteoporosis, hormone-related disorders |
| 08/05/2004 | US20040151779 suspending an active agent-containing powder with active agent hydration less than about 10% in at least one anhydrous, aprotic, hydrophobic, non-polar, low-reactivity vehicle; useful to delivery to an animal for sustained release for long term treatment |
| 08/05/2004 | US20040151776 Novel compositions |
| 08/05/2004 | US20040151774 Therapeutic compositions for drug delivery to and through covering epithelia |
| 08/05/2004 | US20040151773 core containing a complex of the benzimidazole derivative e.g., omeprazole, lansoprazole, pantoprazole, or timoprazole, and ion-exchange resin, and the enteric coating agent having the degree of substitution by an acidic group of less than 30%, |
| 08/05/2004 | US20040151772 Controlled release carvedilol compositions |
| 08/05/2004 | US20040151770 e.g., tiotropium, oxitropium or ipratropium salt and (S)-N-[2-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-piperidin-1-yl]-N-methyl-2-phenylacetamide or salt; respiratory diseases |
| 08/05/2004 | US20040151765 microbocidel has increased activity because of synergy with a chelating agent; pH controlled with buffer so less antimicrobial agent can be used; Vitamin E; surfactant |
| 08/05/2004 | US20040151763 pH adjuster namely citric acid, preservative, and an anti-irritant agent, especially a local anesthetic, analgesic, anesthetic, antipruitic, astringent, hydrocortisone preparation, or keratolytic; feminine wipe |
| 08/05/2004 | US20040151761 adapted for use by a companion animal, such as a dog or cat, to attenuate inflammation, enhance immunity, and enhance longevity |
| 08/05/2004 | US20040151759 Non-animal product containing veterinary formulations |
| 08/05/2004 | US20040151758 fatty acids whose yield energy from beta-oxidation is sufficiently low so that the compound is rendered metabolically low caloric or non-caloric, or a physiologically acceptable ester thereof or a metabolic precursor thereof |
| 08/05/2004 | US20040151757 Use of medium-chain triglycerides (MCT) for optimisation as to nutrition physiology of the fatty acid spectrum in a dietary foodstuff for diabetics |
| 08/05/2004 | US20040151754 Steroid suspensions for intraocular use |
| 08/05/2004 | US20040151744 Avermectin and praziquantel combination therapy |
| 08/05/2004 | US20040151743 Antibacterial composition for topical administration containing antibiotic |
| 08/05/2004 | US20040151732 preventing or treating an abdominal aortic aneurysm or rupture by administering an immunosuppressive agent that inhibits T-lymphocyte reactivity with collagen I, collagen III, or epitope thereof; vaccines; determining risk for developing an AAA |
| 08/05/2004 | US20040151731 preventing or treating an abdominal aortic aneurysm or rupture by administering an immunosuppressive agent that inhibits T-lymphocyte reactivity with collagen I, collagen III, or epitope thereof; vaccines; determining risk for developing an AAA |
| 08/05/2004 | US20040151716 use of an agent which is capable of disrupting a microbial biofilm; may be a physical agent such as sonic energy or an electrical field, or a chemical agent such as guaifenesin; may also contain an antimicrobial compound |
| 08/05/2004 | US20040151712 Modulation of inflammation related to columnar epithelia |
| 08/05/2004 | US20040151710 Topical composition for treating infectious conditions of skin and mucosa |
| 08/05/2004 | US20040151691 viscosity modifier (particularly an ethylene oxide-propylene oxide block polymer), polymerizable component (particularly an acrylate) ; and water; especially for use in dental compositions |
| 08/05/2004 | US20040151690 Block copolymer reduced in impurity content, polymeric carrier, pharmaceutical preparations in polymeric form and process for the preparation of the same |
| 08/05/2004 | US20040151688 Adhesive treatment for epistaxis |
| 08/05/2004 | US20040151687 Poly(diallylamine)-based bile acid sequestrants |
| 08/05/2004 | US20040151671 Topical applying; pressurized container with alcohol foaming agents; acne therapy |
| 08/05/2004 | US20040151670 Heat resistance; mixture including solvent; portable inhaler |
| 08/05/2004 | US20040149022 Noise detection system and method |
| 08/05/2004 | DE20220910U1 Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden Compositions to prevent the misuse of opioids |
| 08/05/2004 | DE10354862A1 Solid pharmaceutical compositions containing ramipril, useful for treating hypertension, heart failure or nephropathy, having low water content to improve stability |
| 08/05/2004 | DE10304374A1 Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament New substituted 2-Aminoimidazole, processes for their preparation, their use as a medicament or diagnostic, and they drug-containing |
| 08/05/2004 | DE10303672A1 Verwendung eines Neuropeptide und Steroide enthaltenden Gemisches zur Behandlung von Störungen des psychosozialen Erlebens und Verhaltens Use of a mixture containing neuropeptides and steroids for the treatment of disorders of psychosocial experience and behavior |
| 08/05/2004 | DE10302763A1 Composition for treating type II diabetes comprises paraffin oil and brandy vinegar |
| 08/05/2004 | DE10301371A1 Treatment or prophylaxis of cardiovascular, cardiopulmonary or renal diseases, e.g. hypertension combined with hyperlipidemia or atherosclerosis, using combination of telmisartan and atorvastatin |
| 08/05/2004 | DE10261067A1 Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure Cholesterol-lowering agents containing an n-3 fatty acid |
| 08/05/2004 | CA2802143A1 Cancer therapy sensitizer |
| 08/05/2004 | CA2798615A1 Novel cocrystallization of hydrochloric acid salt of an active agent |
| 08/05/2004 | CA2553428A1 Pharmaceutical compositions and methods for treating multidrug resistant cancer |
| 08/05/2004 | CA2518888A1 Method for inhibition of necrosis induced by neurotrophin |
| 08/05/2004 | CA2514479A1 Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof |
| 08/05/2004 | CA2514200A1 Amyloid-binding, metal-chelating agents |
| 08/05/2004 | CA2514130A1 Therapeutically active compounds |
| 08/05/2004 | CA2514126A1 Fat substitutes |
| 08/05/2004 | CA2514024A1 Treating androgen deficiency in female (adif)-associated conditions with sarms |
| 08/05/2004 | CA2513881A1 Immunomodulatory compositions |
| 08/05/2004 | CA2513729A1 Co-precipitated amorphous losartan and dosage forms comprising the same |
| 08/05/2004 | CA2513675A1 Methods of identifying modulators of cellular glycosylation using gtrap3-18 |
| 08/05/2004 | CA2513616A1 Composition for oral administration containing capsaicinoids |
| 08/05/2004 | CA2513606A1 Preventive or remedy for intrauterine late embryonic development or pregnancy toxemia |
| 08/05/2004 | CA2513586A1 Method of reducing toxicity of retinoids |
| 08/05/2004 | CA2513575A1 Treatment of benign prostatic hyperplasia using energolytic agents |
| 08/05/2004 | CA2513572A1 Treatment of benign prostatic hyperplasia |
| 08/05/2004 | CA2513433A1 Treatment of diseases with alpha-7 nach receptor full agonists |